Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
JPMA Calls for Legal Framework to Facilitate Use of Pseudonymized Data
The Japan Pharmaceutical Manufacturers Association (JPMA) on November 25 renewed its call for the government to establish a legal framework to facilitate the secondary use of pseudonymized information in R&D. The JPMA made the call as it was invited to…
To read the full story
Related Article
- Japan Needs Special Law on Medical Data to Allow Access Without Patient Consent: JPMA
May 8, 2024
- Legal Changes Needed to Push Use of Pseudonymized Data in Drug R&D: MHLW Working Group
January 16, 2024
- Medical DX Office to Kick Off in September, Explore Better Use of Medical Data for Drug Discovery
August 30, 2023
- Pseudonymised Data Should Fuel Orphan Drug Discovery, but Criteria and Overseas Usage Must Be Discussed: JPMA
July 21, 2023
- Japan Unveils Healthcare DX Timeline, Set to Drive Secondary Data Usage by Drug Makers
June 6, 2023
- Deregulation Panel Urges Discussions on Secondary Use of Medical Data Without Patient Consent
June 2, 2023
- Japan to Launch New Forum to Spur Secondary Use of Medical Data in Drug Discovery
May 30, 2023
- Deregulation Panel Eyes Use of Medical Data “Without Patient Consent”
May 17, 2023
REGULATORY
- Voranigo and More Meds Missing from April Listing Slate; Servier Plans Packaging Change
April 10, 2026
- Health Insurance Reform Bill Enters Diet Debate; OTC-Like Drug Charges in Focus
April 10, 2026
- CEPI Seeks Continued Technology, Funding Ties with Japan
April 10, 2026
- Dialysis Tubing and Medical Device Makers Fret over Long-Term Supply Risks
April 10, 2026
- Japan Moves to Bypass Wholesalers in Fuel Supply to Hospitals
April 10, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…